Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article reviews the development milestones of clascoterone up to its first approval for treating acne vulgaris, reporting no new clinical results for androgenetic alopecia.

This industry update reports on various advancements in therapeutic delivery during July 2018, highlighting active mergers, collaborations, and potential developments across fields like gene therapy, immuno-oncology, and rare diseases treatment; however, no new clinical results are presented.

This review discusses the role of androgens in women's skin-related conditions like acne, hirsutism, and female pattern hair loss, noting the lack of dermatology guidelines for when to pursue endocrinologic evaluation.

This review highlights that clascoterone, a newly FDA-approved topical androgen antagonist, effectively reduces both non-inflammatory and inflammatory acne lesions with no systemic effects, making it a promising new option for acne treatment in both male and female patients.

Clascoterone safely promotes hair growth similar to minoxidil.

This phase 1 study reported that after administering supratherapeutic doses of cortexolone 17α‐propionate, a topical antiandrogen intended for hair loss treatment, there was no effect on the QTc interval, indicating no measurable cardiac safety concerns in the concentration range tested.

Minoxidil is the only FDA-approved topical drug for treating male or female pattern hair loss, and other medications like finasteride and dutasteride can also increase hair growth.

This review presents standardized methods for assessing and tracking hair loss in alopecia areata but reports no clinical results, with the authors noting time limitations in clinical practice.

This review examines medical literature on postfinasteride syndrome and reports no new results; the authors call for more controlled studies on permanent sexual dysfunction and mood changes linked to 5-alpha-reductase inhibitors.

This article discusses central centrifugal cicatricial alopecia, noting its prevalence in women of African descent and highlighting the need for further genetic research to improve treatment options; it reports no new clinical results.

This review explored the new and emerging treatments for androgenetic alopecia and alopecia areata, finding that JAK inhibitors show promise for alopecia areata, while advancements in stem-cell research may eventually lead to new and improved treatments for androgenetic alopecia.

This article discusses various hormonal therapies for acne and provides practical treatment guidelines for managing hormonally related acne, but it reports no new research findings.

This review discusses AR-modulating agents developed between 2012 and 2018, highlighting challenges with ligand-binding domain antagonists and proposing nonconventional approaches targeting other domains as promising strategies.

This review discusses emerging targets for developing drugs to treat hair loss and reports no new clinical results; the authors emphasize the potential for therapies that regenerate hair follicles.

This review discusses current and emerging therapeutic strategies for androgenetic alopecia, noting limited evidence but suggesting areas such as prostaglandin analogs, PRP, and progenitor cell therapies as promising future directions.

This review discusses the potential efficacy of topical antiandrogen therapies for treating androgenetic alopecia and acne vulgaris, finding promising results but highlighting the need for more comprehensive studies.

New drug shows promise for better hair growth in baldness treatment.

This review discusses current treatment options for androgenetic alopecia, noting that most lack robust evidence for efficacy and safety, highlighting the need for more comprehensive studies.

This study evaluated baricitinib 4 mg treatment in severe to very severe alopecia areata, reporting significant scalp hair regrowth by Week 52, especially in short-duration episodes, suggesting treatment should continue for at least a year before assessing failure.

In this analysis of the BRAVE-AA trials, a significant number of patients with severe alopecia areata treated with baricitinib reached complete or nearly complete scalp coverage (SALT score ≤10 or ≤5) over 52 weeks, particularly among those with less severe baseline characteristics.

In this analysis, safety data from two clinical trials showed that baricitinib for severe alopecia areata had predictable side effects like infections and elevated CPK, with some serious adverse events noted at low incidence rates; no deaths were reported.

This study conducted in Europe found that both physicians and patients generally agreed on the severity of alopecia areata, with higher physician-rated severity linked to increased patient-reported burdens such as anxiety, depression, and work impairment.

In this commentary, the authors discuss emerging evidence primarily from pharmacovigilance data and retrospective studies indicating a potential association between GLP-1 receptor agonists, like semaglutide and tirzepatide, and hair loss, although causality remains unproven, prompting recommendations for patient monitoring and further research.

This study found that severe alopecia areata significantly impacts quality of life, mental health, and daily activities, particularly among women and those with a longer disease duration.

In this study on adolescents with severe alopecia areata, baricitinib treatment showed effective scalp, eyebrow, and eyelash regrowth after 52 weeks, benefiting both responders and partial or non-responders, potentially reducing the psychosocial impact of the disease.

In this study, researchers developed a herbal hair dye using henna and other natural ingredients that achieved a color similar to natural black on blonde hair, though further testing on various hair shades is needed to explore its full benefits.

This report describes a severe COVID-19 case in a patient with SLE and nephritis, where hydroxychloroquine improved outcomes after regular use.

This case report describes a patient with SLE and COVID-19, where hydroxychloroquine showed a favorable impact on the virus when taken regularly, leading to clinical improvement and discharge after 24 days.

In this study, researchers found that among adults with severe alopecia, continued treatment with baricitinib for 104 weeks maintained hair regrowth effectively in those who responded at 52 weeks, with improved outcomes noted in some initially non-responders receiving 4 mg.